TALIS BIOMEDICAL CORP (TLIS) Institutional Selling Activity
Several institutional investors tracked by InsiderSet reduced exposure to TALIS BIOMEDICAL CORP (TLIS) during the quarter ended June 30, 2024 based on sequential SEC Form 13F filings.
Institutional selling activity may reflect profit-taking, sector rotation, portfolio rebalancing, or changing conviction levels among major investment firms. InsiderSet tracks quarter-over-quarter holding reductions, full exits, estimated value changes, and historical selling activity using publicly disclosed SEC filing data.
No data available.
Frequently asked questions about TLIS activity
Which institutional owners are buying TLIS?
Institutional owners buying TLIS include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in TLIS activity?
"Buy" means an investor increased their reported position in TLIS compared to the prior reporting period. This reflects growing exposure to TALIS BIOMEDICAL CORP (TLIS) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in TLIS increasing?
Institutional interest in TLIS can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.